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of MPS indemnity means that doctors only need to be a member of 
the MPS at the time something goes wrong; after that, assistance can 
be requested at any time even if the doctor has moved away, taken a 
career break or retired. This provides comfort and peace of mind for 
the doctor and his or her patients. 
In contrast, insurance contracts are complex and are governed by 
the wording of the policy conditions. They also are invariably based 
on the ‘claims made’ principle, which means that cover ceases at the 
end of the policy unless the individual doctor purchases ‘run-off ’ 
cover to meet past incidents that have yet to be reported as claims. It 
is because we so firmly believe in providing our members with what 
is best for them and their patients that we remain so committed to 
our discretionary occurrence-based model of indemnity.
I want to emphasise that the MPS is far more than a provider of 
professional indemnity against claims of negligence. We also assist 
with any problem that arises from a doctor or dentist’s professional 
practice. This might include advice on ethical issues or support with 
disciplinary proceedings, inquests or medical council inquiries.  
One of the core benefits of membership is our confidential 
counselling service, which we fund because the pressures facing those 
working within health care are such that the consequences of even 
the smallest error can be personally devastating for the individual 
doctor.
The MPS has accumulated a vast wealth of experience and 
expertise in medico-legal issues over many years and from more 
than 30 countries – we are truly world experts in our field. The 
MPS is committed to help improve patient safety, and we share our 
expertise to help prevent future problems occurring. We do this 
through lectures, seminars, courses and workshops. For doctors 
our influential publications such as Casebook and Junior Doctor are 
core components of continuing education, and we regularly develop 
materials on important matters such as consent and risk management 
issues.  
We have evolved over the many years we have been in South 
Africa and, with the support of members and the profession, we 
want to evolve further in the future. We hope you will support our 
campaign to persuade the Minister of Health to review the new 
regulations and to allow us to continue to provide a high-quality 
service to our members and their patients. As our attempts to secure 
a solution progress, we will update you on progress regularly via the 
MPS website. No one should be in any doubt of the intensity of our 
activity to find a solution that is acceptable to the profession and to 
government.
South Africa is and will remain of immense importance to the 
MPS. 
A D Mason
Chief Executive
Medical Protection Society
UK
tony.mason@mps.org.uk
Solubility tests and the peripheral 
blood method for screening for sickle-
cell disease
To the Editor: We refer to the paper by Okwi et al.1 Cost benefit 
analysis of screening for sickle cell disease (SCD) using different 
methods cannot be done in isolation, and the following are important 
principles to take into account.
1.    Reasons for screening: (i) early detection of the disease for timely 
intervention to minimise morbidity and mortality; (ii) patient 
and family education on SCD; (iii) genetic counselling as part of 
a long-term strategy to prevent live homozygous SCD (SS) births; 
and (iv) short- and long-term cost saving by means of (i), (ii) and 
(iii) above.
2.    The method of detection needs to be very sensitive. Subjects 
with false-negative results will remain undiagnosed and may well 
present with an acute crisis or organ damage, with major cost 
implications.
The sensitivities of the sickling and solubility tests for detection 
of the sickle cell trait (AS) as reported by the authors were 65% and 
45%, respectively, essentially translating to high 35% and 65% false-
negative rates, an unacceptable scenario regardless of cost saving. 
Clearly the methodologies need to be questioned, since the 
sickling test is sensitive enough to detect AS.1,2 In addition, the article 
advocates that negative sickling tests be regarded as negative for the 
disease, evidently with no further testing required. This means that 
35% of the subjects tested will walk around with undiagnosed AS 
despite having been tested, which defeats the objectives of screening 
as stated above.
The recommendation by the group that the sickling test be the 
preferred and sole method for screening, purely on the basis of 
economics, is disconcerting, while with its observed shortcomings 
the proposed screening method would be of short-term benefit.
We conclude that a cost benefit analysis of methods with such low 
sensitivities is ineffective and futile. 
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Okwi et al. reply: Our cost benefit analysis was not done in isolation, 
as suggested above. The paper was published together with others 
that appeared elsewhere and addressed the issues raised. Sensitisation 
of communities (patient and family education on SCD) and timely 
intervention were covered in a publication in the East African 
Medical Journal.1 Another paper addressing some of these issues was 
published in BMC Blood Disorders.2
All the false negatives with the sickling test were cases of AS 
(carriers), not SS. The sickling test demonstrated all SS cases, as did 
Hb electrophoresis – i.e. sickling was sensitive in SS detection but not 
in AS detection. The sickling test would therefore be sensitive enough 
to detect all the children with SS, who would benefit most since they 
suffer from crisis, while carriers (AS) do not. 
Lastly, the authors state that our article advocated interpreting a 
negative sickling test as the patient being negative for the disease, 
with no further testing required. We did not assume or recommend 
this. Our assumption was that all the children who might accidentally 
be missed by the sickling test and develop symptoms later would be 
tested by Hb electrophoresis.
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We concluded that although the sickling test was not highly 
sensitive, it was more sensitive than solubility and the peripheral 
blood film method.
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Approval of chronic medication
To the Editor: In response to Professor Rayner’s letter to the SAMJ,1 
I would like to point out that Discovery Health was able to resolve 
the case before it was published in your journal. Professor Rayner has 
indicated to us in writing that he would have withdrawn his letter to 
you, had it not been too late to do so.
Discovery Health formulates its funding policies using evidence-
based medicine and in consultation with South Africa’s various 
professional specialist societies and leadership. In the case of diabetes 
mellitus, current SEMDSA guidelines (published in 2009) do not 
recommend the use of HbA1c for diagnosis. We are aware of the 
American Diabetes Association statement referred to by Professor 
Rayner, which recommends the use of HbA1c as a diagnostic test. 
This continues to be debated in national forums, and in fact the 
most recent SEMDSA guidelines released in August 2010 reaffirm 
the position that HbA1c should not be used alone as a diagnostic 
criterion for diabetes or pre-diabetes.
We recognise that individual cases do sometimes merit exceptional 
decisions on clinical grounds. The doctors we employ, some of whom 
are referred to in Professor Rayner’s letter, have the challenging task 
of applying our funding policies in a way that is fair and consistent, 
taking into account both the best interests of individual patients and 
our membership base as a whole. They do so with great care. In this 
specific case, we failed to recognise up front that a clinical exception 
could have been made. Going forward we will endeavour to further 
enhance this aspect of our service.
The sustainability of our members’ medical scheme benefits 
depends on our ability to responsibly apply the principles of evidence-
based medicine wherever possible. We will always actively engage 
with the health care profession and the various representative 
societies to ensure that our funding decisions are clinically sound, 
but as noted above, there are often complex cases in ‘grey areas’ and 
we acknowledge that we do and will make errors in some of these 
situations. We always try to correct these as quickly as possible, and 
we appreciate the feedback we receive, which assists in improving our 
overall approach. We call on all health care professionals to work with 
us in a spirit of co-operation, rather than conflict. Finding the balance 
between what is best for each patient and for our private health care 
system as a whole is a complex task, and needs an active partnership 
between responsible funders and practitioners. 
Jonathan Broomberg
Chief Executive Officer, Discovery Health
jonathanb@discovery.co.za
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